Recombinant Uncharacterized HTH-type transcriptional regulator Rv1353c/MT1396 (Rv1353c, MT1396)

What is Rv1353c and what is its genomic location in Mycobacterium tuberculosis?

Rv1353c is a transcriptional regulator belonging to the TetR family in Mycobacterium tuberculosis. It is located on the negative strand of the MTB genome at positions 1519200-1519985. The gene is 786 base pairs in length, encoding a protein of approximately 261-262 amino acids . Its genomic context is important for understanding its regulatory function, as it operates as part of the complex transcriptional network in MTB. The gene is designated as MT1396 in some annotation systems, particularly in reference to the CDC1551 strain .

What are the basic structural features of the Rv1353c protein?

Rv1353c contains a helix-turn-helix (HTH) DNA-binding domain typical of transcriptional regulators. Structural analysis suggests significant similarity to other bacterial transcription factors, particularly those in the TetR family . The protein has been identified as a true transcription factor (TF) based on domain analysis and functional studies. The protein's structure enables it to bind to specific DNA sequences to regulate the expression of target genes involved in various cellular processes in MTB, including potentially those related to virulence and drug response .

What regulatory networks is Rv1353c involved in?

Rv1353c is predicted to be co-regulated in specific modules, including bicluster_0418 with a residual of 0.49 and bicluster_0511 with a residual of 0.52 . This regulation is potentially mediated by de-novo identified cis-regulatory motifs in each module with e-values of 0.00 and 7.60 for bicluster_0418, and 670.00 and 6,900.00 for bicluster_0511 . The modules where Rv1353c participates are enriched for specific GO terms including phosphopantetheine binding, modified amino acid binding, amide binding, and amino acid binding . These associations suggest that Rv1353c plays a role in regulating metabolic processes crucial for MTB survival.

How does Rv1353c contribute to M. tuberculosis growth and metabolism?

Rv1353c has been found to be important for MTB growth on cholesterol, suggesting its involvement in regulating cholesterol metabolism . This is particularly significant as cholesterol utilization is crucial for MTB persistence during infection. The transcriptional regulator likely controls the expression of genes involved in lipid metabolism pathways. Since MTB can use host cholesterol as a carbon source during infection, Rv1353c may play a role in the adaptation of the bacterium to the host environment. Further research is needed to fully characterize the specific metabolic pathways under Rv1353c regulation.

What is the expression profile of Rv1353c under different conditions?

Expression data from transcription factor overexpression experiments (TFOE) matched with ChIP-seq experiments provide insights into Rv1353c expression patterns . The expression profile is documented in multiple repositories, including data from BioProject PRJNA254351 (accessions GSM1426658, GSM1426659, GSM1426660) within the GEO Series GSE59086 . These datasets were generated using tiling array RNA samples and are described in Rustad et al. 2014, Genome Biology. The expression data reveals that Rv1353c responds to various environmental stimuli and stress conditions, potentially indicating its role in adaptive responses.

What are the identified target genes regulated by Rv1353c?

While comprehensive characterization of all Rv1353c targets is still ongoing, experimental data shows it has both activating and repressive effects on various genes. The gene expression profile when Rv1353c is differentially expressed shows variable effects on nearby genes, with one identified target being repressed with a p-value of 0.0018937 . This indicates that Rv1353c functions as both an activator and repressor depending on the target gene and cellular context. Researchers studying Rv1353c regulation should consider both direct and indirect regulatory effects when interpreting experimental results.

How does Rv1353c influence antibiotic efficacy in M. tuberculosis?

Research has identified Rv1353c as a key transcriptional regulator of multiple drug interaction outcomes in MTB . Using a computational model called INDIGO-MTB (Inferring Drug Interactions using chemogenomics and Orthology), researchers predicted that Rv1353c plays a significant role in modulating how different antibiotics interact when used in combination against MTB . Experimental confirmation shows that upregulation of Rv1353c reduces the antagonism between bedaquiline and streptomycin, two important anti-TB drugs . This finding suggests that Rv1353c could be targeted to enhance drug synergy, potentially improving treatment outcomes.

How can Rv1353c be manipulated to enhance drug synergy?

Based on findings from the INDIGO-MTB model, manipulation of Rv1353c expression levels could be a strategy to enhance the efficacy of drug combinations . Specifically, upregulation of Rv1353c has been shown to reduce the antagonism between bedaquiline and streptomycin . This suggests that targeting Rv1353c through genetic or pharmacological means might be a viable approach to improve combination therapy outcomes. Developing small molecule modulators of Rv1353c activity or expression could potentially enhance the synergistic effects of current anti-TB drug regimens. Such approaches would require careful validation in both in vitro and in vivo models before clinical application.

What methodologies are used to study Rv1353c's role in drug interactions?

Researchers employ several methodologies to study Rv1353c's role in drug interactions:

• Computational modeling: The INDIGO-MTB framework uses transcriptomic profiles of MTB under exposure to individual drugs to predict synergy/antagonism in drug combinations .

• Transcriptomic analysis: RNA sequencing and microarray approaches to monitor changes in gene expression when Rv1353c is manipulated.

• Genetic manipulation: Overexpression or knockout of Rv1353c to study the effects on drug susceptibility.

• Drug interaction assays: Checkerboard assays and time-kill curves to measure how modulation of Rv1353c affects the interaction between different antibiotics.

These approaches collectively help researchers understand how Rv1353c influences drug efficacy and identify potential strategies to enhance treatment outcomes.

What expression systems are most effective for producing recombinant Rv1353c?

For recombinant expression of Rv1353c, E. coli-based systems (particularly BL21(DE3) strains) with T7 promoter-based vectors such as pET series are commonly employed. To optimize expression:

• Consider using a codon-optimized sequence for E. coli, as MTB genes often contain rare codons.

• Express with an N-terminal histidine tag to facilitate purification while minimizing interference with the C-terminal functional domains.

• Induce expression at lower temperatures (16-25°C) to enhance proper folding.

• Include solubility enhancers such as SUMO or MBP tags if inclusion body formation is problematic.

• For functional studies requiring proper folding of the DNA-binding domain, Mycobacterium smegmatis expression systems may provide a more native-like environment.

The choice of expression system should be guided by the intended downstream applications, whether structural studies, DNA-binding assays, or protein-protein interaction analyses.

What are the challenges in purifying functional Rv1353c protein for in vitro studies?

Purification of functional Rv1353c presents several challenges:

• Solubility issues: Like many transcriptional regulators, Rv1353c may have hydrophobic regions that reduce solubility. Using detergents or stabilizing agents may be necessary during purification.

• DNA contamination: As a DNA-binding protein, Rv1353c may co-purify with bacterial DNA. Include DNase treatment and high-salt washes during purification.

• Maintaining native structure: The helix-turn-helix domain is sensitive to denaturation. Avoid harsh elution conditions and consider purification buffers that maintain the native structure (pH 7.5-8.0, 150-300 mM NaCl, 5-10% glycerol).

• Oligomerization state: TetR family regulators often function as dimers or higher-order oligomers. Size exclusion chromatography should be used to verify the oligomeric state.

• Activity verification: Following purification, DNA-binding activity should be verified using electrophoretic mobility shift assays (EMSAs) with predicted target sequences.

A sequential purification approach using affinity chromatography followed by ion exchange and size exclusion typically yields the best results for maintaining functional Rv1353c.

What DNA-binding assays are most appropriate for characterizing Rv1353c interactions with target sequences?

Several DNA-binding assays are suitable for characterizing Rv1353c-DNA interactions:

• Electrophoretic Mobility Shift Assay (EMSA): This is the gold standard for initial characterization, allowing visualization of protein-DNA complex formation and determination of binding affinity. Use fluorescently labeled or radiolabeled DNA fragments containing predicted binding sites.

• DNase I Footprinting: This technique provides nucleotide-resolution mapping of the protected regions where Rv1353c binds.

• Surface Plasmon Resonance (SPR): For quantitative binding kinetics, SPR allows real-time measurement of association and dissociation rates.

• Chromatin Immunoprecipitation (ChIP): For identifying genomic binding sites in vivo, ChIP followed by sequencing (ChIP-seq) can map all binding sites across the MTB genome.

• Systematic Evolution of Ligands by Exponential Enrichment (SELEX): To define the consensus binding motif if unknown.

When designing these assays, consider that TetR-family regulators typically bind palindromic sequences, and binding may be affected by the presence of effector molecules that induce conformational changes in the protein.

How can structural studies of Rv1353c inform drug development strategies?

Structural studies of Rv1353c can significantly advance drug development in several ways:

• Identification of druggable pockets: X-ray crystallography or cryo-EM structures can reveal binding pockets that can be targeted by small molecules to modulate Rv1353c activity.

• Structure-based drug design: Understanding the three-dimensional arrangement of the DNA-binding domain and potential ligand-binding domains enables rational design of molecules that can affect Rv1353c function.

• Allosteric regulation mechanisms: Structural studies may reveal how Rv1353c undergoes conformational changes upon binding to effector molecules, providing insights into natural regulatory mechanisms that can be mimicked by drugs.

• Protein-protein interaction surfaces: If Rv1353c functions within protein complexes, structural studies can identify interaction surfaces that could be targeted to disrupt these complexes.

• Comparison with human proteins: Structural comparison with human transcription factors can ensure the development of selective inhibitors with minimal off-target effects.

The modeling studies already suggest significant structural similarity to the B. subtilis transcription factor SinR, particularly in the amino-terminal helix-turn-helix domain . This provides a starting point for more detailed structural investigations.

What is the potential of Rv1353c as a target for host-directed therapy in tuberculosis?

While direct targeting of Rv1353c offers one therapeutic approach, its involvement in drug interactions opens possibilities for host-directed therapy strategies:

• Modulation of host factors: Identifying host factors that interact with pathways regulated by Rv1353c could reveal targets for host-directed therapy.

• Enhancing drug penetration: Understanding how Rv1353c affects cell envelope composition might help develop adjuvants that enhance drug penetration.

• Immune response modulation: If genes regulated by Rv1353c are involved in immune evasion, host-directed therapies could be developed to counter these effects.

• Metabolic intervention: Since Rv1353c is linked to cholesterol metabolism, host-directed therapies targeting lipid metabolism pathways might synergize with Rv1353c inhibition.

• Combination therapy design: Knowledge of Rv1353c's role in drug interactions can inform the design of host-directed therapies that enhance the efficacy of conventional antibiotics.

Research in this area is still emerging, but the identification of Rv1353c as a regulator of drug interactions suggests it may be a valuable target for developing novel therapeutic approaches.

How does Rv1353c compare to other TetR family regulators in mycobacteria?

Rv1353c shares features with other TetR family regulators in mycobacteria but also has distinct characteristics:

• Sequence conservation: Comparative genomics shows Rv1353c has orthologs in related mycobacterial species, including MAP2394, MAV_1586, MSMEG_2225, and others . This conservation suggests important functional roles.

• Regulon diversity: Unlike some TetR regulators with narrow regulons, Rv1353c appears to influence multiple biological processes, particularly those related to drug responses and metabolism.

• Structural features: While most TetR regulators share the N-terminal DNA-binding domain, the C-terminal ligand-binding domains can vary significantly. These differences affect the specific molecules that can modulate regulator activity.

• Expression patterns: Expression data indicates Rv1353c has a distinct expression profile compared to other TetR regulators, suggesting specialized functions in response to specific environmental cues.

• Role in drug resistance: While many TetR regulators are associated with efflux pump expression and drug resistance, Rv1353c's relationship with drug interactions appears more complex, involving modulation of synergistic or antagonistic effects between drugs.

Researchers should consider these similarities and differences when extrapolating findings from other TetR family studies to Rv1353c.